VCL HB01 - Vical

Drug Profile

VCL HB01 - Vical

Alternative Names: Herpes simplex DNA vaccine; HSV-2 DNA vaccine - Vical; HSV-2 glycoprotein D vaccine - Vical; VCL-HB01

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Washington; Vical
  • Developer Vical
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 11 Jun 2018 Vical discontinued a phase II clinical trial for Herpes simplex virus infections (In adults) in USA (IM) (NCT02837575)
  • 11 Jun 2018 Discontinued - Phase-II for Herpes simplex virus infections (In adults) in USA due to failure to meet primary endpoint (IM)
  • 19 Apr 2017 Vical completes enrolment in a phase II clinical trial for Herpes simplex virus infections in USA (NCT02837575) (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top